CYP1A1 Antibody (OABB02027)

58 kDa

1543

CYP1A1 is involved in phase I xenobiotic and drug metabolism (one substrate of it is theophylline). It is inhibited by fluoroquinolones and macrolides and induced by aromatic hydrocarbons. CYP1A1 is also known as AHH (aryl hydrocarbon hydroxylase). It is involved in the metabolic activation of aromatic hydrocarbons (polycyclic aromatic hydrocarbons, PAH), for example, benzo (a)pyrene (BP), by transforming it to an epoxide. In this reaction, the oxidation of benzo[a]pyrene is catalysed by CYP1A1 to form BP-7, 8-epoxide, which can be further oxidized by epoxide hydrolase (EH) to form BP-7, 8-dihydrodiol. Finally CYP1A1 catalyses this intermediate to form BP-7, 8-dihydrodiol-9, 10-epoxide, which is the ultimate carcinogen. However, an in vivo experiment with gene-deficient mice has found that the hydroxylation of benzo (a)pyrene by CYP1A1 can have an overall protective effect on the DNA, rather than contributing to potentially carcinogenic DNA modifications. This effect is likely due to the fact that CYP1A1 is highly active in the intestinal mucosa, and thus inhibits infiltration of ingested benzo (a)pyrene carcinogen into the systemic circulation.

Polyclonal